This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: YM Bio, Hemispherx, Navidea

Stocks in this article: YMI HEB NAVB INCY

Hemispherex filed the Ampligen resubmission on Aug 1. On Aug. 14, the FDA acknowledged the receipt of the Ampligen resubmission and assigned a six-month review.

To answer Sheff's question, the FDA always moves this quickly when acknowledging a resubmission to a previously issued complete response letter. Hemispherx didn't receive special treatment at all.

The more relevant question to ask: Why did it take Hemispherx three years to refile Ampligen with FDA?

A related question from @ssseeker: "Why is the Hemispherx short position only 2.3% of float if you're so sure Ampligen will not get approved?"

Hemispherx shares trade for less than a buck already. Retail investors might think it fun to short a sub-$1 stock but most institutional investors wouldn't bother. The low short interest reflects indifference, not confidence, in Hemispherx.


@shakes2222 disagreed with my assertion that Navidea Biopharmaceuticals (NAVB) is over-valued because actual Lymphoseek sales -- whenever the product is launched -- will fall far short of expectations.

"So, every analyst has it wrong on NAVB? Does pipeline add value?" he asks. "If pipeline didn't matter, all start-ups would be worthless."

In this case, I do believe that every sell-side analyst covering Navidea will be proven wrong. Their Lymphoseek sales estimates are way too high. I laid out my own sales projections in the column, so we now wait to see who's right. I like my chances.

I didn't discuss Navidea's pipeline because it's thin and not worth much:

RIGScan is a radio-labeled antibody designed to target and collect inside colon cancer cells. A surgeon uses a probe to detect the antibody-soaked cancer tissue and remove it.

Interesting idea except Navidea has been trying to develop RIGScan for 16 years without success. The main problem is that U.S. and European regulators won't approve the agent unless Navidea runs a clinical trial proving that use of RIGScan during colon-cancer surgery improves patient outcomes. An outcomes-based trial in colon-cancer surgery would be very large, lengthy and expensive, so naturally, Navidea has tried to persuade regulators to drop the requirement. That strategy has failed. Assigning value to RIGScan at this point would be overly generous.

AZD4694 is an experimental Alzheimer's imaging agent that binds to beta amyloid plaques and can be detected using a PET scan. Investors get excited when companies develop Alzheimer's-related products because the potential market is so large.

A couple of problems with Navidea's development of AZD4794: 1. The company is well behind Eli Lilly (LLY), which bought Avid Pharmaceuticals and its very similar Alzheimer's imaging agent Amyvid in 2010. Amyvid sales to date have been minimal. 2. Detecting amyloid may be a meaningless exercise because current research hasn't yet proven that using drugs to clear these protein plaques from the brain plays any role whatsoever in improving cognition or memory. So far, all the amyloid-clearing drugs studied -- like Lilly's solaneuzumab and Elan's (ELN) bapineuzumab -- have failed spectacularly.

Altropane is a radio-labeled imaging agent to aid in the diagnosis of Parkinson's disease. Navidea licensed the phase III-ready agent from a private company for $175,000 and 300,000 shares of Navidea common stock. Why do doctors need a radio-labeled agent to detect Parkinson's disease?

Whatever small value you attach to Navidea's pipeline still can't justify the company's current valuation tied much more to Lymphoseek.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
3 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs